Drug-Quality Alert Flags 71 Failed Samples in Himachal Pradesh
A drug-quality alert issued by the Central Drugs Standard Control Organisation (CDSCO) in February 2026 covered samples tested in January. Of 215 samples found not of standard quality nationwide, 71 were manufactured in Himachal Pradesh.
Spurious Products and Enforcement Action
Three products were separately classified as spurious after the companies named on their labels denied making or supplying the batches. State Drug Controller Manish Kapoor said manufacturers had received show-cause notices, the failed batches were to be recalled and investigations were continuing.
Findings Apply to Sampled Batches
The findings concern the batches tested; they do not establish that every medicine made by the named manufacturers, or all products manufactured in Himachal Pradesh, are unsafe.
Important Facts for Exams
- Shared drug-regulation responsibilities: India’s drug regulation is shared: State authorities primarily oversee manufacture, sale and distribution, while CDSCO performs central functions such as import regulation and new-drug approvals.
- Statutory meaning of spurious: Under Section 17B of the Drugs and Cosmetics Act, a drug may be spurious if it is falsely presented as made by another manufacturer.
Originally written on
February 24, 2026
and last modified on
November 19, 2026.
Tags: Central Drugs Standard Control Organisation, Himachal Pradesh, not of standard quality, recall, show-cause notices, spurious products